The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines

EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different...

Full description

Saved in:
Bibliographic Details
Published inJournal of virology Vol. 96; no. 18; p. e0073922
Main Authors Ding, Weiyue, Wang, Chong, Narita, Yohei, Wang, Hongbo, Leong, Merrin Man Long, Huang, Alvin, Liao, Yifei, Liu, Xuefeng, Okuno, Yusuke, Kimura, Hiroshi, Gewurz, Benjamin, Teng, Mingxian, Jin, Shuilin, Sato, Yoshitaka, Zhao, Bo
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 28.09.2022
Subjects
Cell Line, Tumor
Enhancer Elements, Genetic - genetics
Epstein-Barr Virus Infections - genetics
Epstein-Barr Virus Infections - virology
Epstein-Barr Virus Nuclear Antigens - genetics
Genome and Regulation of Viral Gene Expression
Genome Replication and Regulation of Viral Gene Expression
Herpesvirus 4, Human - genetics
Humans
MicroRNAs - metabolism
Neoplasms - virology
Plasmids - chemistry
Plasmids - genetics
Plasmids - metabolism
Viral Proteins - genetics
Virology
Virus Latency - genetics
Epstein-Barr virus
episome
3D genome organization
latency
Online AccessGet full text

Cover

Abstract EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. IMPORTANCE EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.
AbstractList Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. IMPORTANCE EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. IMPORTANCE EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.
EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. IMPORTANCE EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.
Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. IMPORTANCE EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.
Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. IMPORTANCE EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.
Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.
Author Wang, Hongbo
Liao, Yifei
Narita, Yohei
Ding, Weiyue
Gewurz, Benjamin
Huang, Alvin
Teng, Mingxian
Zhao, Bo
Okuno, Yusuke
Wang, Chong
Jin, Shuilin
Liu, Xuefeng
Sato, Yoshitaka
Kimura, Hiroshi
Leong, Merrin Man Long
Author_xml – sequence: 1
  givenname: Weiyue
  surname: Ding
  fullname: Ding, Weiyue
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 2
  givenname: Chong
  surname: Wang
  fullname: Wang, Chong
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 3
  givenname: Yohei
  surname: Narita
  fullname: Narita, Yohei
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 4
  givenname: Hongbo
  surname: Wang
  fullname: Wang, Hongbo
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 5
  givenname: Merrin Man Long
  surname: Leong
  fullname: Leong, Merrin Man Long
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 6
  givenname: Alvin
  surname: Huang
  fullname: Huang, Alvin
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 7
  givenname: Yifei
  surname: Liao
  fullname: Liao, Yifei
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 8
  givenname: Xuefeng
  surname: Liu
  fullname: Liu, Xuefeng
  organization: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
– sequence: 9
  givenname: Yusuke
  surname: Okuno
  fullname: Okuno, Yusuke
  organization: Department of Virology, Nagoya City University Graduate School of Medicine, Nagoya, Aichi, Japan
– sequence: 10
  givenname: Hiroshi
  orcidid: 0000-0001-8063-5660
  surname: Kimura
  fullname: Kimura, Hiroshi
  organization: Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
– sequence: 11
  givenname: Benjamin
  orcidid: 0000-0002-3965-3418
  surname: Gewurz
  fullname: Gewurz, Benjamin
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 12
  givenname: Mingxian
  orcidid: 0000-0002-8536-8941
  surname: Teng
  fullname: Teng, Mingxian
  organization: Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
– sequence: 13
  givenname: Shuilin
  surname: Jin
  fullname: Jin, Shuilin
  organization: Precision Neurology Program, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
– sequence: 14
  givenname: Yoshitaka
  orcidid: 0000-0002-8541-6413
  surname: Sato
  fullname: Sato, Yoshitaka
  organization: Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
– sequence: 15
  givenname: Bo
  orcidid: 0000-0002-8612-5597
  surname: Zhao
  fullname: Zhao, Bo
  organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36094314$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1Lw0AQxRdRtFZvniVHBaP7lU1yEWqpH1DwouJBWCabjd2S7tbdRPC_NzVVVPQ0h_m9x7x5u2jTOqsROiD4lBCanc1fzSnGKctjSjfQgOA8i5OE8E00wJjSOGHZ4w7aDWGOMeFc8G20wwTOOSN8gJ7uZjqaLEOjjY0vwPvowfg2RBM7A6u0j25soz2oxjgbTcGWQcFSh8jYHoxHIThloNFlNO4VY13X0dRYHfbQVgV10PvrOUT3l5O78XU8vb26GY-mMfCMNzEDmlalEJwXBaRMVHlBINE8VYzkQiRQCqaEooJhkvKCA1NAFUkUAK9IlrAhOu99l22x0KXStvFQy6U3C_Bv0oGRPzfWzOSze5V5QtKUsM7gaG3g3UurQyMXJqguB1jt2iDpCiJUCNGhxz0KYUHl3LXedtEkwXLVhuzakB9tSEo79vD7XV8Hfb6_A056QHkXgtfVF_KPH_2FK9PAqpoulan_Fr0Dc9KnhQ
CitedBy_id crossref_primary_10_1093_nar_gkad936
crossref_primary_10_1016_j_ymthe_2023_03_024
crossref_primary_10_1128_jvi_00179_24
crossref_primary_10_1007_s40588_024_00230_z
crossref_primary_10_1002_jmv_28338
crossref_primary_10_1038_s12276_024_01207_0
crossref_primary_10_1371_journal_ppat_1012525
crossref_primary_10_3390_v15051088
crossref_primary_10_1186_s13148_024_01624_y
Cites_doi 10.1371/journal.ppat.1009419
10.1016/S0021-9258(17)42220-4
10.1128/JVI.69.2.1280-1283.1995
10.1038/s41467-019-14152-8
10.1093/embo-reports/kvd026
10.1038/s41586-018-0453-z
10.1126/science.1181369
10.1371/journal.ppat.1002180
10.7554/eLife.18270
10.1016/j.ccell.2020.02.005
10.1371/journal.ppat.1001048
10.1016/j.cell.2006.12.048
10.1371/journal.ppat.1006890
10.1073/pnas.1108892108
10.1038/s41467-021-27894-1
10.1128/JVI.71.9.6611-6618.1997
10.1093/nar/21.19.4483
10.1038/s41580-021-00349-7
10.1128/JVI.00025-06
10.1038/nmeth.3999
10.1126/scitranslmed.3002878
10.1038/s41564-018-0334-0
10.1128/JVI.01390-20
10.1007/978-3-319-22834-1_1
10.1016/j.tim.2019.09.002
10.1128/mBio.01723-19
10.1016/j.chom.2012.06.008
10.1016/S0140-6736(64)91524-7
10.1128/JVI.00530-17
10.1099/0022-1317-79-6-1445
10.1038/s41564-019-0546-y
10.1016/j.cell.2015.01.015
10.1128/JVI.01606-13
10.1128/JVI.73.4.2974-2982.1999
10.1002/(SICI)1097-0215(19961104)68:3%3C285::AID-IJC3%3E3.0.CO;2-Y
10.1126/science.1067799
10.1128/JVI.01718-16
10.1038/s41577-022-00679-3
10.1007/978-3-319-22834-1_5
10.1128/JVI.02209-13
10.1038/sj.bjc.6602968
10.1016/s0002-9440(10)64297-6
10.1128/jvi.76.5.2480-2490.2002
10.1046/j.1365-2249.1999.00836.x
ContentType Journal Article
Copyright Copyright © 2022 American Society for Microbiology.
Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology
Copyright_xml – notice: Copyright © 2022 American Society for Microbiology.
– notice: Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1128/jvi.00739-22
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1098-5514
Editor Frappier, Lori
Editor_xml – sequence: 1
  givenname: Lori
  surname: Frappier
  fullname: Frappier, Lori
ExternalDocumentID PMC9517713
00739-22
36094314
10_1128_jvi_00739_22
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: R01 AI164709
– fundername: NIDCR NIH HHS
  grantid: K99 DE030215
– fundername: NCI NIH HHS
  grantid: R01 CA047006
– fundername: NIAID NIH HHS
  grantid: R01 AI123420
GroupedDBID ---
-~X
0R~
18M
29L
2WC
39C
4.4
53G
5GY
5RE
5VS
85S
AAFWJ
AAGFI
AAYXX
ABPPZ
ACGFO
ACNCT
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CITATION
CS3
DIK
E3Z
EBS
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
N9A
O9-
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
W2D
W8F
WH7
WOQ
YQT
~02
~KM
CGR
CUY
CVF
ECM
EIF
NPM
ABFLS
ABPTK
RHF
UCJ
ZA5
7X8
5PM
ID FETCH-LOGICAL-a484t-3a27fd6644bba736f9b1a5e47c319665ad63c6c2630174b4a3ca2c15caa4f1853
ISSN 0022-538X
1098-5514
IngestDate Thu Aug 21 18:37:45 EDT 2025
Fri Jul 11 10:16:56 EDT 2025
Thu Sep 29 03:43:35 EDT 2022
Thu Apr 03 07:02:37 EDT 2025
Thu Apr 24 23:12:32 EDT 2025
Tue Jul 01 01:32:41 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 18
Keywords Epstein-Barr virus
episome
3D genome organization
latency
Language English
License All Rights Reserved. https://doi.org/10.1128/ASMCopyrightv2
All Rights Reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-a484t-3a27fd6644bba736f9b1a5e47c319665ad63c6c2630174b4a3ca2c15caa4f1853
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The authors declare no conflict of interest.
Weiyue Ding, Chong Wang, and Yohei Narita are co-first authors. Author order was determined by the corresponding author after negotiation.
ORCID 0000-0002-8536-8941
0000-0002-3965-3418
0000-0002-8541-6413
0000-0001-8063-5660
0000-0002-8612-5597
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/9517713
PMID 36094314
PQID 2713312666
PQPubID 23479
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9517713
proquest_miscellaneous_2713312666
asm2_journals_10_1128_jvi_00739_22
pubmed_primary_36094314
crossref_primary_10_1128_jvi_00739_22
crossref_citationtrail_10_1128_jvi_00739_22
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-28
PublicationDateYYYYMMDD 2022-09-28
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-28
  day: 28
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of virology
PublicationTitleAbbrev J Virol
PublicationTitleAlternate J Virol
PublicationYear 2022
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References Longnecker RK (e_1_3_3_3_2) 2013
e_1_3_3_17_2
e_1_3_3_16_2
e_1_3_3_19_2
e_1_3_3_38_2
e_1_3_3_18_2
e_1_3_3_39_2
e_1_3_3_13_2
e_1_3_3_36_2
e_1_3_3_12_2
e_1_3_3_37_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_14_2
e_1_3_3_35_2
e_1_3_3_32_2
e_1_3_3_33_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_10_2
e_1_3_3_31_2
e_1_3_3_40_2
e_1_3_3_6_2
e_1_3_3_5_2
e_1_3_3_8_2
e_1_3_3_7_2
e_1_3_3_28_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_24_2
e_1_3_3_23_2
e_1_3_3_26_2
e_1_3_3_45_2
e_1_3_3_25_2
e_1_3_3_46_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_43_2
e_1_3_3_44_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_41_2
e_1_3_3_21_2
e_1_3_3_42_2
Frappier, L, Goldsmith, K, Bendell, L (B26) 1994; 269
Li, Z, Tsai, MH, Shumilov, A, Baccianti, F, Tsao, SW, Poirey, R, Delecluse, HJ (B21) 2019; 4
Szymula, A, Palermo, RD, Bayoumy, A, Groves, IJ, Ba Abdullah, M, Holder, B, White, RE (B19) 2018; 14
Wang, L, Laing, J, Yan, B, Zhou, H, Ke, L, Wang, C, Narita, Y, Zhang, Z, Olson, MR, Afzali, B, Zhao, B, Kazemian, M (B6) 2020; 94
Wu, H, Ceccarelli, DF, Frappier, L (B10) 2000; 1
Munschauer, M, Nguyen, CT, Sirokman, K, Hartigan, CR, Hogstrom, L, Engreitz, JM, Ulirsch, JC, Fulco, CP, Subramanian, V, Chen, J, Schenone, M, Guttman, M, Carr, SA, Lander, ES (B38) 2018; 561
Tempera, I, Klichinsky, M, Lieberman, PM (B31) 2011; 7
Okuno, Y, Murata, T, Sato, Y, Muramatsu, H, Ito, Y, Watanabe, T, Okuno, T, Murakami, N, Yoshida, K, Sawada, A, Inoue, M, Kawa, K, Seto, M, Ohshima, K, Shiraishi, Y, Chiba, K, Tanaka, H, Miyano, S, Narita, Y, Yoshida, M, Goshima, F, Kawada, JI, Nishida, T, Kiyoi, H, Kato, S, Nakamura, S, Morishima, S, Yoshikawa, T, Fujiwara, S, Shimizu, N, Isobe, Y, Noguchi, M, Kikuta, A, Iwatsuki, K, Takahashi, Y, Kojima, S, Ogawa, S, Kimura, H (B39) 2019; 4
Lee, MA, Diamond, ME, Yates, JL (B11) 1999; 73
Kim, TH, Abdullaev, ZK, Smith, AD, Ching, KA, Loukinov, DI, Green, RD, Zhang, MQ, Lobanenkov, VV, Ren, B (B28) 2007; 128
Tempera, I, Wiedmer, A, Dheekollu, J, Lieberman, PM (B32) 2010; 6
Lieberman-Aiden, E, van Berkum, NL, Williams, L, Imakaev, M, Ragoczy, T, Telling, A, Amit, I, Lajoie, BR, Sabo, PJ, Dorschner, MO, Sandstrom, R, Bernstein, B, Bender, MA, Groudine, M, Gnirke, A, Stamatoyannopoulos, J, Mirny, LA, Lander, ES, Dekker, J (B35) 2009; 326
Hodin, TL, Najrana, T, Yates, JL (B5) 2013; 87
Sharp, TV, Schwemmle, M, Jeffrey, I, Laing, K, Mellor, H, Proud, CG, Hilse, K, Clemens, MJ (B20) 1993; 21
Pich, D, Mrozek-Gorska, P, Bouvet, M, Sugimoto, A, Akidil, E, Grundhoff, A, Hamperl, S, Ling, PD, Hammerschmidt, W (B23) 2019; 10
Dekker, J, Rippe, K, Dekker, M, Kleckner, N (B34) 2002; 295
Mumbach, MR, Rubin, AJ, Flynn, RA, Dai, C, Khavari, PA, Greenleaf, WJ, Chang, HY (B37) 2016; 13
Chen, HS, Martin, KA, Lu, F, Lupey, LN, Mueller, JM, Lieberman, PM, Tempera, I (B25) 2014; 88
Chau, CM, Zhang, XY, McMahon, SB, Lieberman, PM (B33) 2006; 80
Arvey, A, Tempera, I, Tsai, K, Chen, HS, Tikhmyanova, N, Klichinsky, M, Leslie, C, Lieberman, PM (B24) 2012; 12
Wood, CD, Veenstra, H, Khasnis, S, Gunnell, A, Webb, HM, Shannon-Lowe, C, Andrews, S, Osborne, CS, West, MJ (B36) 2016; 5
Harada, S, Kieff, E (B14) 1997; 71
Cen, O, Longnecker, R (B17) 2015; 391
Tsuge, I, Morishima, T, Morita, M, Kimura, H, Kuzushima, K, Matsuoka, H (B43) 1999; 115
Epstein, MA, Achong, BG, Barr, YM (B1) 1964; 283
Zhao, B, Zou, J, Wang, H, Johannsen, E, Peng, CW, Quackenbush, J, Mar, JC, Morton, CC, Freedman, ML, Blacklow, SC, Aster, JC, Bernstein, BE, Kieff, E (B13) 2011; 108
Chiang, AK, Tao, Q, Srivastava, G, Ho, FC (B41) 1996; 68
Kim, KD, Tanizawa, H, De Leo, A, Vladimirova, O, Kossenkov, A, Lu, F, Showe, LC, Noma, KI, Lieberman, PM (B7) 2020; 11
Longnecker, RK, Cohen, JI (B2) 2013; 2
Davidson, IF, Peters, JM (B30) 2021; 22
Kirchmaier, AL, Sugden, B (B4) 1995; 69
Wang, LW, Jiang, S, Gewurz, BE (B16) 2017; 91
Cohen, JI, Fauci, AS, Varmus, H, Nabel, GJ (B3) 2011; 3
Zhang, Y, Ohyashiki, JH, Takaku, T, Shimizu, N, Ohyashiki, K (B40) 2006; 94
Xiong, J, Cui, BW, Wang, N, Dai, YT, Zhang, H, Wang, CF, Zhong, HJ, Cheng, S, Ou-Yang, BS, Hu, Y, Zhang, X, Xu, B, Qian, WB, Tao, R, Yan, F, Hu, JD, Hou, M, Ma, XJ, Wang, X, Liu, YH, Zhu, ZM, Huang, XB, Liu, L, Wu, CY, Huang, L, Shen, YF, Huang, RB, Xu, JY, Wang, C, Wu, DP, Yu, L, Li, JF, Xu, PP, Wang, L, Huang, JY, Chen, SJ, Zhao, WL (B42) 2020; 37
Morgan, SM, Tanizawa, H, Caruso, LB, Hulse, M, Kossenkov, A, Madzo, J, Keith, K, Tan, Y, Boyle, S, Lieberman, PM, Tempera, I (B27) 2022; 13
Ohashi, M, Hayes, M, McChesney, K, Johannsen, E (B15) 2021; 17
Skinner, CM, Ivanov, NS, Barr, SA, Chen, Y, Skalsky, RL (B22) 2017; 91
De Leo, A, Calderon, A, Lieberman, PM (B12) 2020; 28
Oyoshi, MK, Nagata, H, Kimura, N, Zhang, Y, Demachi, A, Hara, T, Kanegane, H, Matsuo, Y, Yamaguchi, T, Morio, T, Hirano, A, Shimizu, N, Yamamoto, K (B44) 2003; 162
Klein, G, Teramoto, N, Manneborg-Sandlund, A, Lennette, ET, Chen, F, Szeles, A, Löwbeer, M, Szekely, L, Pokrovskaja, K, Ehlin-Henriksson, B (B45) 1998; 79
Zhang, Y, Zhang, X, Dai, HQ, Hu, H, Alt, FW (B29) 2022
Frappier, L (B9) 2015; 391
Wu, H, Kapoor, P, Frappier, L (B8) 2002; 76
Lee, N, Moss, WN, Yario, TA, Steitz, JA (B18) 2015; 160
References_xml – ident: e_1_3_3_16_2
  doi: 10.1371/journal.ppat.1009419
– ident: e_1_3_3_27_2
  doi: 10.1016/S0021-9258(17)42220-4
– ident: e_1_3_3_5_2
  doi: 10.1128/JVI.69.2.1280-1283.1995
– ident: e_1_3_3_8_2
  doi: 10.1038/s41467-019-14152-8
– ident: e_1_3_3_11_2
  doi: 10.1093/embo-reports/kvd026
– ident: e_1_3_3_39_2
  doi: 10.1038/s41586-018-0453-z
– ident: e_1_3_3_36_2
  doi: 10.1126/science.1181369
– ident: e_1_3_3_32_2
  doi: 10.1371/journal.ppat.1002180
– ident: e_1_3_3_37_2
  doi: 10.7554/eLife.18270
– ident: e_1_3_3_43_2
  doi: 10.1016/j.ccell.2020.02.005
– ident: e_1_3_3_33_2
  doi: 10.1371/journal.ppat.1001048
– ident: e_1_3_3_29_2
  doi: 10.1016/j.cell.2006.12.048
– ident: e_1_3_3_20_2
  doi: 10.1371/journal.ppat.1006890
– ident: e_1_3_3_14_2
  doi: 10.1073/pnas.1108892108
– ident: e_1_3_3_28_2
  doi: 10.1038/s41467-021-27894-1
– ident: e_1_3_3_15_2
  doi: 10.1128/JVI.71.9.6611-6618.1997
– ident: e_1_3_3_21_2
  doi: 10.1093/nar/21.19.4483
– ident: e_1_3_3_31_2
  doi: 10.1038/s41580-021-00349-7
– ident: e_1_3_3_34_2
  doi: 10.1128/JVI.00025-06
– ident: e_1_3_3_38_2
  doi: 10.1038/nmeth.3999
– ident: e_1_3_3_4_2
  doi: 10.1126/scitranslmed.3002878
– ident: e_1_3_3_40_2
  doi: 10.1038/s41564-018-0334-0
– ident: e_1_3_3_7_2
  doi: 10.1128/JVI.01390-20
– ident: e_1_3_3_10_2
  doi: 10.1007/978-3-319-22834-1_1
– ident: e_1_3_3_13_2
  doi: 10.1016/j.tim.2019.09.002
– ident: e_1_3_3_24_2
  doi: 10.1128/mBio.01723-19
– volume-title: Epstein-Barr virus
  year: 2013
  ident: e_1_3_3_3_2
– ident: e_1_3_3_25_2
  doi: 10.1016/j.chom.2012.06.008
– ident: e_1_3_3_2_2
  doi: 10.1016/S0140-6736(64)91524-7
– ident: e_1_3_3_23_2
  doi: 10.1128/JVI.00530-17
– ident: e_1_3_3_46_2
  doi: 10.1099/0022-1317-79-6-1445
– ident: e_1_3_3_22_2
  doi: 10.1038/s41564-019-0546-y
– ident: e_1_3_3_19_2
  doi: 10.1016/j.cell.2015.01.015
– ident: e_1_3_3_6_2
  doi: 10.1128/JVI.01606-13
– ident: e_1_3_3_12_2
  doi: 10.1128/JVI.73.4.2974-2982.1999
– ident: e_1_3_3_42_2
  doi: 10.1002/(SICI)1097-0215(19961104)68:3%3C285::AID-IJC3%3E3.0.CO;2-Y
– ident: e_1_3_3_35_2
  doi: 10.1126/science.1067799
– ident: e_1_3_3_17_2
  doi: 10.1128/JVI.01718-16
– ident: e_1_3_3_30_2
  doi: 10.1038/s41577-022-00679-3
– ident: e_1_3_3_18_2
  doi: 10.1007/978-3-319-22834-1_5
– ident: e_1_3_3_26_2
  doi: 10.1128/JVI.02209-13
– ident: e_1_3_3_41_2
  doi: 10.1038/sj.bjc.6602968
– ident: e_1_3_3_45_2
  doi: 10.1016/s0002-9440(10)64297-6
– ident: e_1_3_3_9_2
  doi: 10.1128/jvi.76.5.2480-2490.2002
– ident: e_1_3_3_44_2
  doi: 10.1046/j.1365-2249.1999.00836.x
– volume: 391
  start-page: 3
  year: 2015
  end-page: 34
  ident: B9
  article-title: EBNA1
  publication-title: Curr Top Microbiol Immunol
  doi: 10.1007/978-3-319-22834-1_1
– volume: 91
  year: 2017
  ident: B16
  article-title: Epstein-Barr virus LMP1-mediated oncogenicity
  publication-title: J Virol
  doi: 10.1128/JVI.01718-16
– volume: 391
  start-page: 151
  year: 2015
  end-page: 180
  ident: B17
  article-title: Latent Membrane Protein 2 (LMP2)
  publication-title: Curr Top Microbiol Immunol
  doi: 10.1007/978-3-319-22834-1_5
– year: 2022
  ident: B29
  article-title: The role of chromatin loop extrusion in antibody diversification
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-022-00679-3
– volume: 17
  year: 2021
  ident: B15
  article-title: Epstein-Barr virus nuclear antigen 3C (EBNA3C) interacts with the metabolism sensing C-terminal binding protein (CtBP) repressor to upregulate host genes
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1009419
– volume: 69
  start-page: 1280
  year: 1995
  end-page: 1283
  ident: B4
  article-title: Plasmid maintenance of derivatives of oriP of Epstein-Barr virus
  publication-title: J Virol
  doi: 10.1128/JVI.69.2.1280-1283.1995
– volume: 13
  start-page: 187
  year: 2022
  ident: B27
  article-title: The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-27894-1
– volume: 561
  start-page: 132
  year: 2018
  end-page: 136
  ident: B38
  article-title: The NORAD lncRNA assembles a topoisomerase complex critical for genome stability
  publication-title: Nature
  doi: 10.1038/s41586-018-0453-z
– volume: 88
  start-page: 1703
  year: 2014
  end-page: 1713
  ident: B25
  article-title: Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site
  publication-title: J Virol
  doi: 10.1128/JVI.02209-13
– volume: 28
  start-page: 150
  year: 2020
  end-page: 162
  ident: B12
  article-title: Control of viral latency by episome maintenance proteins
  publication-title: Trends Microbiol
  doi: 10.1016/j.tim.2019.09.002
– volume: 94
  year: 2020
  ident: B6
  article-title: Epstein-Barr virus episome physically interacts with active regions of the host genome in lymphoblastoid cells
  publication-title: J Virol
  doi: 10.1128/JVI.01390-20
– volume: 3
  start-page: 107fs7
  year: 2011
  ident: B3
  article-title: Epstein-Barr virus: an important vaccine target for cancer prevention
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3002878
– volume: 11
  start-page: 877
  year: 2020
  ident: B7
  article-title: Epigenetic specifications of host chromosome docking sites for latent Epstein-Barr virus
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-14152-8
– volume: 73
  start-page: 2974
  year: 1999
  end-page: 2982
  ident: B11
  article-title: Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus
  publication-title: J Virol
  doi: 10.1128/JVI.73.4.2974-2982.1999
– volume: 5
  year: 2016
  ident: B36
  article-title: MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs
  publication-title: Elife
  doi: 10.7554/eLife.18270
– volume: 21
  start-page: 4483
  year: 1993
  end-page: 4490
  ident: B20
  article-title: Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/21.19.4483
– volume: 4
  start-page: 2475
  year: 2019
  end-page: 2486
  ident: B21
  article-title: Epstein-Barr virus ncRNA from a nasopharyngeal carcinoma induces an inflammatory response that promotes virus production
  publication-title: Nat Microbiol
  doi: 10.1038/s41564-019-0546-y
– volume: 326
  start-page: 289
  year: 2009
  end-page: 293
  ident: B35
  article-title: Comprehensive mapping of long-range interactions reveals folding principles of the human genome
  publication-title: Science
  doi: 10.1126/science.1181369
– volume: 80
  start-page: 5723
  year: 2006
  end-page: 5732
  ident: B33
  article-title: Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF
  publication-title: J Virol
  doi: 10.1128/JVI.00025-06
– volume: 162
  start-page: 1629
  year: 2003
  end-page: 1638
  ident: B44
  article-title: Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection
  publication-title: Am J Pathol
  doi: 10.1016/s0002-9440(10)64297-6
– volume: 79
  start-page: 1445
  year: 1998
  end-page: 1452
  ident: B45
  article-title: Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line
  publication-title: J Gen Virol
  doi: 10.1099/0022-1317-79-6-1445
– volume: 4
  start-page: 404
  year: 2019
  end-page: 413
  ident: B39
  article-title: Defective Epstein-Barr virus in chronic active infection and haematological malignancy
  publication-title: Nat Microbiol
  doi: 10.1038/s41564-018-0334-0
– volume: 76
  start-page: 2480
  year: 2002
  end-page: 2490
  ident: B8
  article-title: Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1
  publication-title: J Virol
  doi: 10.1128/jvi.76.5.2480-2490.2002
– volume: 6
  year: 2010
  ident: B32
  article-title: CTCF prevents the epigenetic drift of EBV latency promoter Qp
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1001048
– volume: 295
  start-page: 1306
  year: 2002
  end-page: 1311
  ident: B34
  article-title: Capturing chromosome conformation
  publication-title: Science
  doi: 10.1126/science.1067799
– volume: 10
  year: 2019
  ident: B23
  article-title: First days in the life of naive human B lymphocytes infected with Epstein-Barr virus
  publication-title: mBio
  doi: 10.1128/mBio.01723-19
– volume: 94
  start-page: 599
  year: 2006
  end-page: 608
  ident: B40
  article-title: Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6602968
– volume: 2
  year: 2013
  ident: B2
  publication-title: Epstein-Barr virus ;8th ed ;Lippincott Williams & Wilkins ;Philadelphia, PA
– volume: 283
  start-page: 702
  year: 1964
  end-page: 703
  ident: B1
  article-title: Virus particles in cultured lymphoblasts from Burkitt’s lymphoma
  publication-title: Lancet
  doi: 10.1016/S0140-6736(64)91524-7
– volume: 128
  start-page: 1231
  year: 2007
  end-page: 1245
  ident: B28
  article-title: Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome
  publication-title: Cell
  doi: 10.1016/j.cell.2006.12.048
– volume: 269
  start-page: 1057
  year: 1994
  end-page: 1062
  ident: B26
  article-title: Stabilization of the EBNA1 protein on the Epstein-Barr virus latent origin of DNA replication by a DNA looping mechanism
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(17)42220-4
– volume: 13
  start-page: 919
  year: 2016
  end-page: 922
  ident: B37
  article-title: HiChIP: efficient and sensitive analysis of protein-directed genome architecture
  publication-title: Nat Methods
  doi: 10.1038/nmeth.3999
– volume: 160
  start-page: 607
  year: 2015
  end-page: 618
  ident: B18
  article-title: EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA
  publication-title: Cell
  doi: 10.1016/j.cell.2015.01.015
– volume: 91
  year: 2017
  ident: B22
  article-title: An Epstein-Barr virus microRNA blocks interleukin-1 (IL-1) signaling by targeting IL-1 receptor 1
  publication-title: J Virol
  doi: 10.1128/JVI.00530-17
– volume: 7
  year: 2011
  ident: B31
  article-title: EBV latency types adopt alternative chromatin conformations
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1002180
– volume: 87
  start-page: 13020
  year: 2013
  end-page: 13028
  ident: B5
  article-title: Efficient replication of Epstein-Barr virus-derived plasmids requires tethering by EBNA1 to host chromosomes
  publication-title: J Virol
  doi: 10.1128/JVI.01606-13
– volume: 22
  start-page: 445
  year: 2021
  end-page: 464
  ident: B30
  article-title: Genome folding through loop extrusion by SMC complexes
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-021-00349-7
– volume: 115
  start-page: 385
  year: 1999
  end-page: 392
  ident: B43
  article-title: Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line
  publication-title: Clin Exp Immunol
  doi: 10.1046/j.1365-2249.1999.00836.x
– volume: 1
  start-page: 140
  year: 2000
  end-page: 144
  ident: B10
  article-title: The DNA segregation mechanism of Epstein-Barr virus nuclear antigen 1
  publication-title: EMBO Rep
  doi: 10.1093/embo-reports/kvd026
– volume: 68
  start-page: 285
  year: 1996
  end-page: 290
  ident: B41
  article-title: Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin’s disease
  publication-title: Int J Cancer
  doi: 10.1002/(SICI)1097-0215(19961104)68:3%3C285::AID-IJC3%3E3.0.CO;2-Y
– volume: 71
  start-page: 6611
  year: 1997
  end-page: 6618
  ident: B14
  article-title: Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation
  publication-title: J Virol
  doi: 10.1128/JVI.71.9.6611-6618.1997
– volume: 14
  year: 2018
  ident: B19
  article-title: Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naive B cells, and facilitates recruitment of transcription factors to the viral genome
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1006890
– volume: 12
  start-page: 233
  year: 2012
  end-page: 245
  ident: B24
  article-title: An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2012.06.008
– volume: 37
  start-page: 403
  year: 2020
  end-page: 419.e6
  ident: B42
  article-title: Genomic and transcriptomic characterization of natural killer T cell lymphoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.02.005
– volume: 108
  start-page: 14902
  year: 2011
  end-page: 14907
  ident: B13
  article-title: Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1108892108
SSID ssj0014464
Score 2.4596703
Snippet EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. Epstein-Barr virus...
Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing...
SourceID pubmedcentral
proquest
asm2
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e0073922
SubjectTerms Cell Line, Tumor
Enhancer Elements, Genetic - genetics
Epstein-Barr Virus Infections - genetics
Epstein-Barr Virus Infections - virology
Epstein-Barr Virus Nuclear Antigens - genetics
Genome and Regulation of Viral Gene Expression
Genome Replication and Regulation of Viral Gene Expression
Herpesvirus 4, Human - genetics
Humans
MicroRNAs - metabolism
Neoplasms - virology
Plasmids - chemistry
Plasmids - genetics
Plasmids - metabolism
Viral Proteins - genetics
Virology
Virus Latency - genetics
Title The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines
URI https://www.ncbi.nlm.nih.gov/pubmed/36094314
https://journals.asm.org/doi/10.1128/jvi.00739-22
https://www.proquest.com/docview/2713312666
https://pubmed.ncbi.nlm.nih.gov/PMC9517713
Volume 96
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbQIiQuiDeFBRkEpypL4jh2coRSVGDhtAt7QIpsN1GDIFkl7UrLr2fGTtK0tNLCxarSyUOZL_PyPAh5yXzlx4mC7ztUwuMG5GDic-2ZBNSp8qU2CRY4f_4iZqf841l0tk7ltdUlS31kfu-sK_kfrsIx4CtWyf4DZ_uLwgH4DfyFFTgM65V5PD1vcGCl91bV9fhrUa-a8bRcIC9rF-5rh4EfY00vZjvZBFhL6HW8wSivO2OCobxjTIXfY7ViWdwwEP-unYnyLSsuV-t9njYKPVlUrWbEeLPCQISV-dUiK7ZpZ0Cqq2EUAhxY3JiJh5IVndrQjgkGveKEKfYqRYtsKG3d_NoOVfFuKc6wMuHHRXFkNxI9V7m82Sx7S4n1qYXWqWFxCmen9uyUgYa-zsCLsB73h0_9JhN4wrxrJo-P3tVFsPj18N6grFXzi20aLn95I9tJtQMr5eQ2udUyir5xWLlDrmXlXXLDDRy9vEe-A2LoEDHUAoF2iKEDxNA1YmhR0m3EUIcYioihFjH3yen76clk5rXzNTzFY770QsVkPhdgEWutZCjyRAcqyrg0KJdFpOYiNMIwAUpAcs1VaBQzQWSU4jnaeQ_IQVmV2SNCOZNzyQ3PkyiHxSg_iyMwdoNcYyf8aERe4DtM24-nSXexaUTG3RtOTduhHgel_NxD_aqnPnedWfbQPe-YlYLoxP0wVWbVqkkZBmgCsFDFiDx0zOuvFApMuQ34iMgNtvYE2JZ985-yWNj27OCzSLjy4ys-3xNyc_1BHZKDZb3KnoKhu9TPLFz_AJWOp_I
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Epstein-Barr+Virus+Enhancer+Interaction+Landscapes+in+Virus-Associated+Cancer+Cell+Lines&rft.jtitle=Journal+of+virology&rft.au=Ding%2C+Weiyue&rft.au=Wang%2C+Chong&rft.au=Narita%2C+Yohei&rft.au=Wang%2C+Hongbo&rft.date=2022-09-28&rft.issn=0022-538X&rft.eissn=1098-5514&rft.volume=96&rft.issue=18&rft_id=info:doi/10.1128%2Fjvi.00739-22&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_jvi_00739_22
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon